Bridgeway Capital Management’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Bridgeway Capital Management’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,900	Closed	-$11.6K	–	1486
2023 Q1	$11.6K	Sell	3,900 -6,000	-61%	-$22.1K	﹤0.01%	1368
2022 Q4	$49.5K	Sell	9,900 -5,000	-34%	-$19.1K	﹤0.01%	1297
2022 Q3	$97K	Hold	14,900	–	–	﹤0.01%	1275
2022 Q2	$108K	Sell	14,900 -1,000	-6%	-$9.1K	﹤0.01%	1214
2022 Q1	$235K	Buy	+15,900	New	+$404K	﹤0.01%	1143

Other funds holding LABP

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bridgeway Capital Management's LABP Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2023, closing a stake of 3,900 shares — an estimated $11.6K sold.

Bridgeway Capital Management first reported a position in LABP in Q1 2022 and held it in 5 quarters. The position peaked at $235K in Q1 2022. 8 funds tracked by Wall St. Rank hold LABP as of Q2 2023.

Bridgeway Capital Management reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 3,900 Landos Biopharma, Inc. Common Stock shares in Q2 2023, an estimated $11.6K.
Bridgeway Capital Management first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Bridgeway Capital Management's Landos Biopharma, Inc. Common Stock position peaked at $235K in Q1 2022.
8 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.